HA Burris

Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with <i>PIK3CA</i> mutant advanced solid tumors: preliminary efficacy and safety in patients with <i>PIK3CA</i> mutant ER-positive (ER+) metastatic breast cancer (MBC)

Dejan Juric, Guillem Argilés, HA Burris et al. · Cancer Research · 2012 · 32 citations

Breast Oncology, Solid Tumors, Pathology +17

Summary of data from in vitro and phase I vinorelbine (Navelbine) studies.

HA Burris, Suzanne M. Fields · PubMed · 1994 · 32 citations

A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer.

S. Vukelja, Hope S. Rugo, C Vogel et al. · Cancer Research · 2009 · 27 citations

Breast Oncology, Immunology, Phase Ii Study +20

A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer.

IE Krop, M. Mita, HA Burris et al. · Cancer Research · 2009 · 14 citations

Breast Oncology, Immunology, Immunotherapeutics +16

Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study

Dejan Juric, AM Gonzalez-Angulo, HA Burris et al. · Cancer Research · 2013 · 12 citations

Breast Oncology, Pathology, Preliminary Safety +18